featured
Intravenous and Intracranial GD2-CAR T-Cell Therapy for H3K27M-Altered Diffuse Midline Gliomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Nature 2024 Nov 13;[EPub Ahead of Print], M Monje, J Mahdi, R Majzner, KW Yeom, LM Schultz, RM Richards, V Barsan, KW Song, J Kamens, C Baggott, M Kunicki, SP Rietberg, AS Lim, A Reschke, S Mavroukakis, E Egeler, J Moon, S Patel, H Chinnasamy, C Erickson, A Jacobs, AK Duh, R Tunuguntla, DD Klysz, C Fowler, S Green, B Beebe, C Carr, M Fujimoto, AK Brown, AG Petersen, C McIntyre, A Siddiqui, N Lepori-Bui, K Villar, K Pham, R Bove, E Musa, WD Reynolds, A Kuo, S Prabhu, L Rasmussen, TT Cornell, S Partap, PG Fisher, CJ Campen, G Grant, L Prolo, X Ye, B Sahaf, KL Davis, SA Feldman, S Ramakrishna, C MackallFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.